CGRP Inhibitors: How the New Migraine Medications Work

For decades, preventing migraine meant borrowing drugs that were designed for something else entirely. Beta-blockers built for blood pressure. Anticonvulsants built for seizures. Antidepressants built for depression. They helped some patients, but they were never actually made for migraine, and the side effects reflected that. CGRP inhibitors represent the first new migraine medication class engineered specifically to target the biology of an attack rather than sedating the nervous system in the hope that fewer attacks slip through.

This article is for anyone whose old preventives failed, caused side effects they couldn’t tolerate, or simply never worked well enough. We’ll walk through what CGRP actually is, the treatment options now available, and what a realistic outcome looks like.

This article is for general educational purposes and is not a substitute for a medical evaluation. Please consult a physician before starting or changing any medication.

What Is CGRP and Why Does It Matter in Migraine?

CGRP stands for calcitonin gene-related peptide, a small protein released around the trigeminal nerve, the main pain pathway involved in migraine. During an attack, CGRP levels rise, blood vessels around the brain dilate, and pain signaling ramps up. When the attack resolves, CGRP levels fall back down. That correlation, rising with the attack and falling as it ends, is what first pointed researchers toward this molecule decades ago.

The logic is straightforward: if you can block CGRP itself, or the receptor it binds to, you interrupt the process driving the attack rather than dampening the entire nervous system the way older preventives do. That’s the entire premise behind CGRP migraine treatment, and it’s why these drugs tend to come with a different, generally milder side effect profile than the medications they’re replacing.

A CGRP antagonist is a drug that blocks that binding, either by attaching to the CGRP molecule so it can’t reach its target or by occupying the receptor so CGRP has nowhere to land. Several different molecules now do this job, delivered in different ways, which makes the treatment landscape genuinely useful for patients who’ve run out of good options.

Monoclonal Antibodies for Prevention

The first wave of CGRP inhibitors to reach the market were injectable monoclonal antibodies, and four are currently FDA-approved: erenumab, fremanezumab, galcanezumab, and eptinezumab (PMC systematic review). Three are self-injected monthly or quarterly; the fourth, eptinezumab, is given as an infusion once every three months. All four were built to reduce how often attacks happen, not to stop one already in progress.

The realistic expectation matters here. These medications generally cut migraine days by a few days per month compared to placebo in clinical trials, a meaningful improvement for someone with frequent attacks, but not a guarantee of zero migraines. Most neurologists ask patients to stick with a CGRP medication trial for two to three months before judging whether it’s actually working, since the full benefit often builds gradually rather than showing up after the first dose.

Gepants: Oral Options for Acute and Preventive Use

Gepants are oral, small-molecule CGRP antagonist drugs taken as tablets rather than injections. Ubrogepant (Ubrelvy) is approved only for treating an attack once it starts. Rimegepant (Nurtec) does both: it can be taken at the first sign of an attack, or every other day on a schedule to prevent attacks altogether, making it the first drug approved for both acute and preventive migraine treatment.

How does Nurtec work? It dissolves on the tongue without water and directly blocks the CGRP receptor, interrupting the pain and inflammation cascade rather than relying on the vessel-constricting mechanism older triptan medications use. That distinction matters for a meaningful group of patients. Because gepants don’t constrict blood vessels the way triptans do, they’re an option for people who can’t take triptans due to cardiovascular risk.

The Ubrelvy vs Nurtec comparison comes up constantly, and there isn’t a universal winner. Ubrelvy lets you take a second dose two hours after the first if the pain hasn’t resolved, which some patients value as a built-in backup plan. Nurtec’s dissolving tablet works without water and doubles as a preventive option, which matters more for people managing frequent attacks. The right choice depends more on attack pattern and personal response than on any general ranking between the two.

Who Is a Good Candidate?

The usual clinical threshold for considering a CGRP inhibitor is four or more migraine days a month, or a history of chronic migraine, combined with previous preventives that either failed to help or caused side effects the patient couldn’t live with. That said, individual circumstances vary, and this is a conversation for a neurologist rather than a self-assessment based on a symptom count alone.

The practical realities are worth knowing upfront. Insurance plans frequently require documented trials of older, cheaper preventives first, a process called step therapy, before approving a CGRP migraine medication, and prior authorization paperwork is common. Manufacturer savings programs exist for most of these drugs and can meaningfully offset out-of-pocket costs while insurance approval is pending. At a neurology clinic, this usually means a visit to review prior treatment history, followed by paperwork submitted on the patient’s behalf rather than left for the patient to navigate alone.

Some situations call for extra caution: pregnancy, plans to become pregnant, and significant cardiovascular disease are all reasons a neurologist may recommend a different approach or additional monitoring, since long-term safety data in these groups is still limited. That conversation belongs with a physician who knows the full medical history, not a forum thread or a manufacturer’s website.

Side Effects and What to Expect

Nurtec side effects are generally mild: nausea is the most common complaint when used for an acute attack, while nausea, stomach pain, and indigestion show up more often with the preventive dosing schedule. Emgality side effects and Adjevri side effects center mainly on injection-site reactions, redness or soreness where the shot is given, though erenumab in the same drug class has also been linked to constipation in a subset of patients.

None of these are trivial to the person experiencing them. Still, compared to the fatigue, weight gain, or mood changes that some older preventives caused, this class is generally better tolerated as a group. Anything that doesn’t settle within the first few doses, or any signs of a significant allergic reaction, is worth reporting to your prescriber promptly. Long-term data on these medications is still accumulating because the class is relatively young, which is another reason ongoing follow-up with a neurologist matters more than a one-time prescription.

CGRP medications are generally safe to combine with acute treatments like triptans when needed, though your neurologist will confirm this based on your specific regimen. Keeping a simple migraine diary, noting attack frequency, severity, and any side effects, remains the most reliable way to judge whether a preventive is actually earning its place in your routine rather than guessing from memory a few months in.

Talk to a Texas Neurologist About Your Options

One failed medication doesn’t mean migraine is untreatable, and it’s worth saying that directly because a lot of patients quietly give up after a bad experience with an older preventive. The right choice among CGRP inhibitors, gepants, and other options depends on how often attacks happen, what other health conditions are in the picture, and what your insurance will cover, all of which is easier to sort through with a specialist than alone.

For patients who don’t respond well to CGRP-targeted treatment, Lone Star Neurology also offers Botox and other preventive approaches as part of a broader plan. Migraine rarely travels alone, either; patients managing frequent attacks sometimes also deal with vestibular migraine, where the vertigo itself becomes the dominant symptom rather than head pain, and that combination calls for a treatment plan that addresses both. Head pain this severe deserves the same scrutiny as cluster headaches, which are sometimes mistaken for migraine early on despite needing a different treatment approach entirely. 

Lone Star Neurology treats migraine patients across Texas, including Dallas, Plano, Frisco, McKinney, Allen, Richardson, Carrollton, Denton, Fort Worth, Arlington, Austin, San Antonio, and Houston. Call 214-619-1910 or book online.

Disclaimer: This article is intended for general educational purposes and does not replace a medical evaluation. Do not start, stop, or switch any migraine medication without first consulting a Lone Star Neurology healthcare provider.